A midlife longevity drug?

Matt Kaeberlein and Brian K. Kennedy
Additional contact information
Matt Kaeberlein: University of Washington, Seattle, Washington 98195, USA. kaeber@u.washington.edu
Brian K. Kennedy: University of Washington, Seattle, Washington 98195, USA. kaeber@u.washington.edu

Nature, 2009, vol. 460, issue 7253, 331-332

Abstract: The small molecule rapamycin, already approved for clinical use for various human disorders, has been found to significantly increase lifespan in mice. Is this a step towards an anti-ageing drug for people?

Date: 2009
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/460331a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:460:y:2009:i:7253:d:10.1038_460331a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/460331a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().